Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

             Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the “Offer”). The offering period of the Offer is scheduled to expire at 5:00 p.m., New York City time, on Monday, December 16, 2019, unless it is extended further under the circumstances set forth in the Agreement and Plan of Merger, dated as of February 22, 2019, by and among Roche Holdings, Inc., 022019 Merger Subsidiary, Inc., and Spark. Closing of the tender offer is conditioned upon customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and there being validly tendered and received, and not validly withdrawn, a majority of the outstanding Spark Shares. MacKenzie Partners, Inc. is acting as information agent ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Date: Thursday, 04 09, 2020; Speaker: Zeynup Gumus, Assistant Professor, Ichan School of Medicine at Mount Sinai; https://cbiit.webex.com/mw3300/mywebex/default.do?
Source: NIH Calendar of Events - Category: American Health Source Type: events
Publication date: Available online 31 March 2020Source: Materials Today: ProceedingsAuthor(s): K. Senthil Kannan, S. Gayathri Devi, Prithiviraj Nagarajan, G. Flora, R. Ranadevan
Source: Materials Today: Proceedings - Category: Materials Science Source Type: research
Publication date: Available online 31 March 2020Source: CellAuthor(s): Marcus Ruscetti, John P. Morris, Riccardo Mezzadra, James Russell, Josef Leibold, Paul B. Romesser, Janelle Simon, Amanda Kulick, Yu-jui Ho, Myles Fennell, Jinyang Li, Robert J. Norgard, John E. Wilkinson, Direna Alonso-Curbelo, Ramya Sridharan, Daniel A. Heller, Elisa de Stanchina, Ben Z. Stanger, Charles J. Sherr, Scott W. Lowe
Source: Cell - Category: Cytology Source Type: research
Daniel J. IkensonSome people talk about trade as though it were an end in itself. It ’s not. Trade is a means to an end.We trade so that we can specialize. We specialize so that we can produce more. We produce more so that we can consume and save more. That is how we create wealth and raise living standards. Just like electricity or machinery or expertise, trade is a tool we use to leverage our physical, mental, and creative abilities to obtain more efficiently more of the things we need and want. When we remove barriers to trade, we create greater scope for specialization, which means we can produce more v...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Andras Komaromy, Balazs Reider, Gabor Jarvas, Andras Guttman
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Publication date: Available online 31 March 2020Source: Clinica Chimica ActaAuthor(s): Yueting Xiong, Chao Shi, Xiaohui Liu, Pengyuan Yang
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of appr...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Biotechnology | Blindness | Brain | Canada Health | Cancer | Cancer & Oncology | Children | Diabetes | Endocrinology | Gene Therapy | Genetics | Haemophilia | Hemophilia | Hospitals | Infectious Diseases | International Medicine & Public Health | Japan Health | Mergers and Aquisitions | Neurology | Neuroscience | Opthalmology | Palliative | Pharmaceuticals | Science | Switzerland Health | Tax | USA Health | WHO